0AL Stock Overview
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Agile Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.24 |
52 Week High | US$38.00 |
52 Week Low | US$7.24 |
Beta | 1.13 |
1 Month Change | 0% |
3 Month Change | -23.09% |
1 Year Change | -80.94% |
3 Year Change | -99.83% |
5 Year Change | -99.12% |
Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
0AL | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 2.3% | 1.9% |
1Y | -80.9% | -25.9% | 7.3% |
Return vs Industry: 0AL underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 0AL underperformed the German Market which returned 5.9% over the past year.
Price Volatility
0AL volatility | |
---|---|
0AL Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0AL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0AL's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 22 | Al Altomari | https://www.agiletherapeutics.com |
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. Fundamentals Summary
0AL fundamental statistics | |
---|---|
Market cap | €8.07m |
Earnings (TTM) | -€18.62m |
Revenue (TTM) | €11.80m |
0.7x
P/S Ratio-0.4x
P/E RatioIs 0AL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0AL income statement (TTM) | |
---|---|
Revenue | US$12.94m |
Cost of Revenue | US$7.31m |
Gross Profit | US$5.62m |
Other Expenses | US$26.04m |
Earnings | -US$20.42m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.97 |
Gross Margin | 43.48% |
Net Profit Margin | -157.83% |
Debt/Equity Ratio | -16.0% |
How did 0AL perform over the long term?
See historical performance and comparison